VTI ETF Performance: The Vanguard Total Stock Market ETF (VTI) has increased by 2.40% over the past week and 17.52% year-to-date, with a notable gain of 1.1% on Monday, coinciding with a record high for the Nasdaq Composite.
Investor Activity: VTI experienced a net inflow of $703 million over the last five trading days, indicating strong investor interest, with an average trading volume of 4.07 million shares.
Analyst Consensus and Price Target: VTI is rated as a Moderate Buy by analysts, with an average price target of $376.33, suggesting an upside potential of 11.53%.
Top Holdings and Potential: The ETF's largest holdings include Nvidia, Microsoft, and Apple, while its top five stocks with the highest upside potential are FlexShopper, FibroBiologics, Biodesix, BioAtla, and Cibus.
Wall Street analysts forecast BDSX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDSX is 30.00 USD with a low forecast of 20.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast BDSX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDSX is 30.00 USD with a low forecast of 20.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 8.330
Low
20.00
Averages
30.00
High
40.00
Current: 8.330
Low
20.00
Averages
30.00
High
40.00
Canaccord
Buy
downgrade
$30 -> $20
Al Analysis
2025-09-19
Reason
Canaccord
Price Target
$30 -> $20
Al Analysis
2025-09-19
downgrade
Buy
Reason
Canaccord lowered the firm's price target on Biodesix to $20 from $30 and keeps a Buy rating on the shares. The firm updated its model to reflect its 20-for-1 reverse split which reduces the amount of outstanding shares to 8 million from 156 million. Importantly, the company appears to have an at-the-market facility it could leverage to help it maintain operations through potentially cash flow breakeven/profitability.
Scotiabank
Outperform
to
NULL
downgrade
$3 -> $2
2025-05-21
Reason
Scotiabank
Price Target
$3 -> $2
2025-05-21
downgrade
Outperform
to
NULL
Reason
Scotiabank lowered the firm's price target on Biodesix to $2 from $3 and keeps an Outperform rating on the shares. The company's Q1 revenue miss and FY25 revenue guidance reduction can be attributed to the shift in the company's commercial strategy, the analyst tells investors. The firm continues to believe the market for lung nodule risk assessment is a multi-billion-dollar opportunity that is under-penetrated and the company faces minimal competition.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BDSX
Unlock Now
William Blair
William Blair
Outperform -> Market Perform
downgrade
2025-05-14
Reason
William Blair
William Blair
Price Target
2025-05-14
downgrade
Outperform -> Market Perform
Reason
William Blair downgraded Biodesix to Market Perform from Outperform. The company lowered its full-year revenue guidance by 12% at the midpoint to reflect slower salesforce rep hiring and slightly higher rep attrition than expected, the analyst tells investors in a research note. The firm believes the Q1 update puts the stock in "show me status" until likely the latter part of 2025 or early 2026. The shares "may have a ceiling on them" even at what is a "very discounted valuation," contends William Blair.
Canaccord
Kyle Mikson
Buy
downgrade
2025-05-14
Reason
Canaccord
Kyle Mikson
Price Target
2025-05-14
downgrade
Buy
Reason
Canaccord analyst Kyle Mikson lowered the firm's price target on Biodesix to $1.50 from $2.50 and keeps a Buy rating on the shares. The firm said the target decrease is driven by lower near- and long-term revenue estimates after the company posted Q1 results that were below expectations.
About BDSX
Biodesix, Inc. is a diagnostic solutions company. Biodesix Diagnostic Tests, marketed as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. The Nodify Lung Nodule Risk Assessment assesses a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. Nodify CDT and Nodify XL2 tests are marketed as Nodify Lung Nodule Risk Assessment. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests are marketed as part of its IQLung testing strategy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
